Saturday 17 October 2026
Export IMNN’s income statement to Excel — free account
Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.02
0.04
−3.77%
Follow IMNN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 2 | 3 | 4 | 2 | 3 | 5 | 3 |
P/S ratio |
— | — | — | 21.44 | 87.96 | 45.40 | 74.74 | 49.66 | 43.04 | 16.65 |
Altman Z-Score |
— | — | — | (12.47) | (5.04) | (12.15) | (11.18) | (8.51) | (7.94) | (13.10) |
Altman Z″-Score (non-manufacturers) |
— | — | — | (25.05) | (9.34) | (27.27) | (26.28) | (18.14) | (16.72) | (30.54) |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | (2.57) | — | 8.75 | — |
P/Operating CF |
— | — | — | (2.14) | (8.64) | (6.08) | (6.65) | 4.08 | (5.11) | (1.79) |
P/B ratio |
— | — | — | 0.37 | 0.79 | 1.22 | 2.57 | 1.19 | 0.81 | 1.24 |
Price to Tangible BV |
— | — | — | 0.39 | 0.82 | 1.37 | 3.05 | 1.36 | 0.90 | 2.23 |
EV/Sales |
— | — | — | (37.83) | 0.89 | 18.94 | 60.95 | 13.27 | (2.66) | 10.68 |
EV/EBITDA |
— | — | — | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 |
EV/Operating CF |
— | — | — | 0.82 | (0.03) | (0.61) | (1.50) | (0.94) | 0.08 | (0.29) |
EV/FCF |
— | — | — | 0.81 | (0.03) | (0.61) | (1.48) | (0.92) | 0.08 | (0.29) |
Quick Ratio |
1.90 | 1.23 | 2.12 | 3.41 | 7.30 | 2.54 | 1.88 | 4.52 | 3.91 | 0.51 |
Current Ratio |
2.32 | 1.67 | 2.47 | 3.66 | 7.67 | 2.79 | 2.06 | 4.61 | 3.92 | 0.54 |
Net Debt/EBITDA |
0.63 | 0.32 | 0.77 | 1.23 | 2.17 | 0.76 | 0.35 | 0.89 | 1.35 | 0.22 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 10.49% | 7.91% | 10.48% | 20.80% | 20.10% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.16 | 0.10 | 0.21 | 0.55 | 0.45 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Operating CF/Net income |
0.96 | 1.01 | 0.97 | 0.64 | 0.78 | 0.73 | 1.20 | 0.59 | 0.80 | 0.83 |
Capex/Depreciation |
(0.40) | (0.04) | (0.58) | (0.29) | (0.33) | (0.02) | (0.32) | (0.25) | (0.07) | (0.05) |
Interest Coverage |
— | — | (106.70) | (4.96) | (36.86) | (14.30) | (14.76) | (29.59) | (201.18) | (28.56) |
| (256.41%) | (211.21%) | (91.37%) | (84.34%) | (55.83%) | (129.54%) | (95.15%) | (49.97%) | (124.13%) | (162.69%) | |
| (131.74%) | (117.72%) | (59.23%) | (60.83%) | (37.23%) | (56.68%) | (39.59%) | (25.18%) | (52.95%) | (55.22%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (107.08%) | (214.70%) | (167.77%) | (493.72%) | (455.08%) | (532.96%) |
Return on Tangible Assets |
(218.63%) | (494.67%) | (168.21%) | (131.54%) | (45.49%) | (173.73%) | (192.67%) | (53.51%) | (113.45%) | 639.63% |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.71 | 2.92 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,346.74% | 2,123.86% | 2,268.96% | 2,613.06% | 2,373.10% | 2,615.74% | 2,924.62% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,737.58% | 2,177.58% | 1,528.32% | 1,600.04% | 1,939.90% | 1,177.94% | 1,305.36% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.06 | 0.05 | 0.06 | 0.10 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 534.60% | 751.94% | 370.28% | 458.34% | 926.86% | 221.04% | 302.20% |
Graham Net Nets |
— | — | — | 2.06 | 0.77 | 0.00 | (0.20) | 0.09 | 0.16 | (2.36) |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (344.41%) | (46.12%) | (94.27%) | (44.90%) | (46.05%) | (96.47%) | (265.47%) |
Free Cash Flow Yield |
— | — | — | (217.91%) | (37.60%) | (68.90%) | (55.14%) | (28.92%) | (77.52%) | (221.47%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.91 | 1.20 | 3.06 | 4.48 | 5.56 | 12.82 | 52.63 |
Operating CF per Share |
(6.54) | (17.16) | (27.42) | (42.16) | (38.97) | (95.59) | (181.37) | (78.24) | (426.72) | (1,934.67) |
Capex per Share |
(0.13) | (0.03) | (0.65) | (0.49) | (0.75) | (0.12) | (3.13) | (1.54) | (0.99) | (6.58) |
Free Cash Flow per Share |
(6.68) | (17.18) | (28.07) | (42.64) | (39.72) | (95.70) | (184.50) | (79.78) | (427.71) | (1,941.25) |
Cash per Share |
4.14 | 5.34 | 22.62 | 62.51 | 118.64 | 105.04 | 133.05 | 306.79 | 619.69 | 453.07 |
Shareholders Equity per Share |
3.33 | 3.86 | 19.30 | 53.53 | 134.03 | 113.90 | 130.34 | 231.79 | 684.73 | 707.98 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.33 | 3.86 | 19.30 | 53.53 | 134.03 | 113.90 | 130.34 | 231.79 | 684.73 | 707.98 |
Free Cash Flow |
(14.18) | (18.88) | (19.47) | (23.36) | (16.54) | (15.64) | (20.61) | (7.18) | (16.68) | (18.44) |
Working Capital |
6.10 | 3.22 | 10.85 | 26.74 | 45.18 | 12.07 | 8.34 | 22.02 | 18.11 | (3.91) |
Capital Expenditures |
(0.28) | (0.03) | (0.45) | (0.27) | (0.31) | (0.02) | (0.35) | (0.14) | (0.04) | (0.06) |
Net Current Asset Value |
5.50 | 2.54 | 9.71 | 22.13 | 33.69 | (0.09) | (7.48) | 2.14 | 3.50 | (19.61) |
EV/EBIT |
— | — | — | 0.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.54 | 0.62 | 0.04 | 0.70 | 0.28 | 0.08 | 0.13 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.32 | 1.33 | 1.03 | 1.67 | 1.97 | 4.04 | 2.73 | 3.01 | 3.35 | 2.73 |
Cash ROIC |
(89.49%) | (186.66%) | (66.96%) | (34.27%) | (14.89%) | (39.38%) | (55.13%) | (12.40%) | (32.79%) | (167.20%) |
Accounts Receivable Turnover |
— | — | — | 4.21 | 7.68 | 0.00 | 11.15 | 8.15 | 17.12 | 8.27 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
— | — | — | 0.12 | 0.07 | — | 0.04 | 0.06 | 0.03 | 0.06 |
Average Payables |
1.35 | 2.41 | 3.55 | 3.07 | 2.40 | 2.55 | 2.94 | 3.22 | 3.15 | 2.85 |
Average Assets |
11.00 | 15.82 | 32.95 | 59.01 | 55.79 | 37.90 | 42.57 | 47.19 | 39.18 | 39.94 |
Average Common Equity |
5.65 | 8.82 | 21.36 | 42.56 | 37.20 | 16.59 | 17.71 | 23.78 | 16.72 | 13.56 |
Columns are period end dates